Abstract
Lacosamid is a newly approved anticonvulsant drug for the treatment of focal and secondary generalized seizures in young patients over the age of 16 years. Its major effect is probably to accelerate the slow inactivation of the sodium channels in neurons. Data on young children receiving therapy with Lacosamid are not yet available. We report our first experiences using Lacosamid in young children with therapy-resistant epilepsy. A group of 16 children with the following diagnoses was treated: CSWS, symptomatic focal seizures, LGS, Angelman syndrome, inversion duplication of chromosome 15. Children's age at the onset of treatment with Lacosamid: 8 boys (age: 72–201 months; ˜130 months) and 8 girls (age: 22–152 months; ˜83 months). Nearly all children were experiencing daily seizures before treatment was started.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
